Global MRSA Drugs Market Opportunities and Forecast 2020-2027
  • DLR2217
  • 18 March, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global MRSA Drugs Market, By Type (Tetracycline, Folate antagonist, Lipopeptides, Cephalosporin, Oxazolidinone, Lipoglycopeptide), opportunities and forecast 2020-2027

Market Overview

Methicillin-resistant Staphylococcus aureus or (MRSA) is skin infection which occurs mostly in healthcare facilities and hospitals. The infection is treated with commonly used antibiotics and it is highly contagious. The infection is difficult to treat as it is resistant to the commonly-used antibiotics including methicillin. The aging people are highly vulnerable to MRSA infections, particularly in the hospital setting as the weak immune system makes such people easily prone to the diseases and infections. Early detection of these infections and growing awareness of the treatment drugs are expected to positively aid in growth of the market in the coming years.

The surge in number of infections and the infectious diseases is generating unmet needs in market. This has driven the non-governmental and government-based institutes to take initiatives to develop antibiotics by providing necessary funding to companies and research institutes. Several nations across globe are actively giving funds to develop the antibacterial drugs and also fight drug resistance and its surveillance. Such aid encourages companies and research institutes to invest more in the antibiotic research, thus resulting in growth of the market.

Segment Overview

Tetracyclines prevent bacterial protein synthesis via reversibly binding to bacterial 30S ribosomes. The drugs act against the Gram-positive and the Gram-negative bacteria; though, most of drugs develop resistance, thus indicate limited activity. Few commonly recommend drugs that treat infection include doxycycline, tetracycline, and minocycline.

Regional Overview

The North America dominated MRSA drugs market in 2019 and accounted for over 71% of the market share. Much of region’s growth can be accredited to availability of better the healthcare infrastructure coupled with presence of favourable reimbursement policies and co-pay support programs for patients. With adoption of favourable regulatory initiatives for approval of antibiotics, numerous drug developers in region are concentrating on developing the new treatment options.

Competitor overview

Currently, the market is rising at slow pace because of increased use of the generics. The inaccessibility of effective treatment choices and improved development of the drug resistance is leading to the unmet needs in market. This has pushed numerous vendors to engage vigorously in R&D activities. Moreover, the market is anticipated to witness entry of several new companies during forecast period. The vendors are concentrating on both the manufacturers as well as the market their products with the high safety and efficiency profile, to gain competitive edge in market.

Basilea Pharmaceutica, one of leading drug manufacturer, entered into license agreement for anti-MRSA antibiotic Zevtera with the Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. Such key initiatives being adopted by manufacturers is likely to propel growth of MRSA drugs over the forecast period.

Key Players
  1. Allergan
  2. Merck
  3. Pfizer
  4. Theravance Biopharma
  5. Basilea Pharmaceutica,
  6. The Medicines Company,
  7. Theravance Biopharma,

Market Segmentation

By Drug Class
  • Tetracycline
  • Folate antagonist
  • Lipopeptides
  • Cephalosporin
  • Oxazolidinone
  • Lipoglycopeptide
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA

Report You Might be Interested

Choose License Type

  • USD
  • GBP
  • EURO
  • INR
Credit card Logo

Happy To Assist You

Have a Question? email us at

[email protected]

Or Call Us On

US +1 360 851 1343

IND +91 880 579 4934